دسترسی یکساله به بیش از ۵۰۰ ژورنال روز جهان موجود در سامانه
-
http://medilib.ir
- ﻣﺪﺕ ﺯﻣﺎﻥ : 365 ﺭﻭﺯ
قیمت : 3,800,000 تومان- قیمت ویژه : 1,900,000تومان
What Dobbs Means for Patients with Breast Cancer
Nicole T. Christian, M.D., and Virginia F. Borges, M.D.
doi : 10.1056/NEJMp2209249
Responding to the Escalating Cybersecurity Threat to Health Care
Eric Perakslis, Ph.D.
doi : 10.1056/NEJMp2205144
“Fertility Fraud� Legislation — A Turning Point for Informed Consent?
Dov Fox, J.D., D.Phil., L.L.M.
doi : 10.1056/NEJMp2206007
Updated Health Warnings for Alcohol — Informing Consumers and Reducing Harm
Anna H. Grummon, Ph.D., M.S.P.H., and Marissa G. Hall, Ph.D., M.S.P.H.
doi : 10.1056/NEJMp2206494
Losing Contact — Covid-19, Telemedicine, and the Patient–Provider Relationship
Shannon M. MacDonald, M.D., and Julia Berv, P.A.-C.
doi : 10.1056/NEJMp2206471
Fractional Flow Reserve or Intravascular Ultrasonography to Guide PCI
Bon-Kwon Koo, M.D., Xinyang Hu, M.D., Jeehoon Kang, M.D., Jinlong Zhang, M.D., Jun Jiang, M.D., Joo-Yong Hahn, M.D., Chang-Wook Nam, M.D., Joon-Hyung Doh, M.D., Bong-Ki Lee, M.D., Weon Kim, M.D., Jinyu Huang, M.D., Fan Jiang, M.D.,
doi : 10.1056/NEJMoa2201546
In patients with coronary artery disease who are being evaluated for percutaneous coronary intervention (PCI), procedures can be guided by fractional flow reserve (FFR) or intravascular ultrasonography (IVUS) for decision making regarding revascularization and stent implantation. However, the differences in clinical outcomes when only one method is used for both purposes are unclear.
Nirmatrelvir Use and Severe Covid-19 Outcomes during the Omicron Surge
Ronen Arbel, Ph.D., Yael Wolff Sagy, Ph.D., Moshe Hoshen, Ph.D., Erez Battat, M.B.A., Gil Lavie, M.D., Ruslan Sergienko, M.A., Michael Friger, Ph.D., Jacob G. Waxman, M.D., Noa Dagan, M.D., Ran Balicer, M.D., Yatir Ben-Shlomo, B.Sc., Alon Peretz, M.D.,
doi : 10.1056/NEJMoa2204919
The oral protease inhibitor nirmatrelvir has shown substantial efficacy in high-risk, unvaccinated patients infected with the B.1.617.2 (delta) variant of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Data regarding the effectiveness of nirmatrelvir in preventing severe coronavirus disease 2019 (Covid-19) outcomes from the B.1.1.529 (omicron) variant are limited.
Dolutegravir in Pregnancy as Compared with Current HIV Regimens in the United States
Kunjal Patel, D.Sc., Yanling Huo, M.S., Jennifer Jao, M.D., Kathleen M. Powis, M.D., Paige L. Williams, Ph.D., Deborah Kacanek, Sc.D., Lynn M. Yee, M.D., Ellen G. Chadwick, M.D., Stephanie Shiau, Ph.D., Denise L. Jacobson, Ph.D., Sean S. Brummel, Ph.D., Leila Sultan-Beyer, M.D.,
doi : 10.1056/NEJMoa2200600
Bedaquiline–Pretomanid–Linezolid Regimens for Drug-Resistant Tuberculosis
Francesca Conradie, M.B., B.Ch., Tatevik R. Bagdasaryan, M.D., Sergey Borisov, M.D., Pauline Howell, M.D., Lali Mikiashvili, M.D., Nosipho Ngubane, M.D., Anastasia Samoilova, M.D., Sergey Skornykova, M.D., Elena Tudor, M.D., Ebrahim Variava, M.D., Petr Yablonskiy, Ph.D., Daniel Everitt, M.D.,
doi : 10.1056/NEJMoa2119430
The bedaquiline–pretomanid–linezolid regimen has been reported to have 90% efficacy against highly drug-resistant tuberculosis, but the incidence of adverse events with 1200 mg of linezolid daily has been high. The appropriate dose of linezolid and duration of treatment with this agent to minimize toxic effects while maintaining efficacy against highly drug-resistant tuberculosis are unclear.
Subacute Combined Degeneration from Nitrous Oxide Use
Joseph Y. Yoon, M.D., and Joshua P. Klein, M.D., Ph.D.
doi : 10.1056/NEJMicm2119871
Severe Subcutaneous Emphysema
Sulakshan Rasiah, B.M., B.S., and Max Whitchurch, M.B., B.S.
doi : 10.1056/NEJMicm2200611
Telescoping the Diagnostic Process
Clement D. Lee, M.D., Evan Shirey, M.D., Brittany Guttadauria, M.D., and Chén C. Kenyon, M.D., M.S.H.P.
doi : 10.1056/NEJMcps2205676
Linezolid for Drug-Resistant Tuberculosis
Guy Thwaites, F.R.C.P., and Nhung V. Nguyen, M.D., Ph.D.
doi : 10.1056/NEJMe2208554
Audio Interview: Covid-19 and the WHO
Eric J. Rubin, M.D., Ph.D., Lindsey R. Baden, M.D., Soumya Swaminathan, M.B., B.S., M.D., and Stephen Morrissey, Ph.D.
doi : 10.1056/NEJMe2211564
Building Black Wealth — The Role of Health Systems in Closing the Gap
Eugenia South, M.D., Atheendar Venkataramani, M.D., Ph.D., and George Dalembert, M.D.
doi : 10.1056/NEJMms2209521
Pretomanid in the Treatment of Patients with Tuberculosis in the United States
doi : 10.1056/NEJMc2119461
Sequential Stem Cell–Kidney Transplantation in Schimke Immuno-osseous Dysplasia
doi : 10.1056/NEJMc2209527
